Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29
Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company, announced that it anticipates releasing topline results from two Phase 3 clinical trials evaluating DFD-29 for the treatment of moderate to severe papulopustular rosacea. The results are expected to be announced during the week of July 10, 2023.
DFD-29 is a Minocycline Hydrochloride Modified Release Capsule being developed in collaboration with Dr. Reddy's Laboratories Ltd. The Phase 3 clinical program consists of two multicenter trials, MVOR-1 and MVOR-2, which aim to support regulatory submissions in the United States and Europe.